Partnership to advance novel therapeutic, drug delivery platform for Parkinson’s disease

A health care innovation company and a clinical-stage biotech company have announced a partnership to advance a novel apomorphine therapeutic in combination with a wearable drug delivery platform to treat Parkinson’s disease.

According to a joint release from Enable Injections and Serina Therapeutics, SER-252 is an investigational therapy developed with the latter’s POZ platform, which is designed to provide continuous dopaminergic stimulation (CDS) to the central nervous system. CDS has been shown to reduce severity of levodopa-related motor complications, or dyskinesia, in PD.

“Serina’s proprietary POZ platform addresses the limitations of medications that have narrow therapeutic ranges – like many therapies used to treat neurological disorders — while Enable’s wearable drug delivery platform overcomes the shortcomings of standard IV injections and infusions, which can be painful, complex and time-consuming,” Serina Therapeutics Chief Development Officer Randall Moreadith, MD, PhD, told Healio in an email.

“Together, we aim to bring those living with, and treating, Parkinson’s a more convenient and less disruptive treatment experience.”

Developed by Enable, enFuse is a drug delivery platform designed to deliver large volumes of medications subcutaneously, rather than intravenously. Enable is working with a number of pharmaceutical partners to conduct clinical trials and plan for joint commercial launch of their therapies in combination with the enFuse technology, according to the release.

Serina additionally stated plans to advance SER-252 for clinical testing in 2025.

“The technology and benefits of enFuse have the potential to significantly reduce many of the burdens associated with the current standard of care for Parkinson’s,” Enable Injections Chairman and CEO Mike Hooven said in the release. “We greatly look forward to bringing those living with, and treating, Parkinson’s disease.”